Knockdown of ZEB1 Inhibits Hypertrophic Scarring Through Suppressing the Wnt/β-Catenin Signaling Pathway in a Mouse Model.

Rui Jin,Zhizhong Deng,Fei Liu,Lin Lu,Feixue Ding,Yirui Shen,Hayson Chenyu Wang,Mengling Chang,Zhiyou Peng,Xiao Liang
DOI: https://doi.org/10.1097/prs.0000000000011190
2023-01-01
Abstract:Background: Hypertrophic scars (HS) cause functional impairment and cosmetic deformities following surgeries or burns (30% to 94%). There is no target therapy yet because the pathogenesis of HS progression is not well-known. In tissue fibrosis, Zinc finger E‐box binding homeobox 1 (ZEB1) abnormal upregulation is an important cause for extracellular matrix (ECM) overexpression, which is the main molecular change in HS. Therefore, we hypothesized that ZEB1-knockdown inhibits HS formation. Methods: ZEB1 expression in human HS and TGF-β1-induced fibroblasts were identified by PCR and western blotting. ZEB1 was knockdown by siRNA in HS fibroblasts (HSFs) and mouse HS model (C57/BL6, male, 8-12 weeks). After 8-hour-transfection, HSFs were subjected to PCR, western blotting and CCK-8, apoptosis, migration and contraction assays. Mice HS were analyzed by HE staining, PCR and western blotting after 56 days. Results: ZEB1 was upregulated in HS tissue (2.0-fold; p < 0.001). ZEB1 knockdown inhibited HSFs activity (0.6 to 0.7-fold; p < 0.001), the expression of fibrotic markers (0.4 to 0.6-fold; p < 0.001) and β-catenin, cyclinD1 and c-Myc expression (0.5-fold; p < 0.001). In mouse HS models, HS skin thickness was thinner (1.60 ± 0.40 mm vs. 4.04 ± 0.36 mm; p < 0.001) after ZEB1 knockdown. Conclusions: Knockdown of ZEB1 inhibits HS formation both in vitro and in vivo. However, this is an in vitro/mouse model and more validation is needed. Clinical Relevance Statement: The discovery of ZEB1 as a mediator of HS formation might be a potential therapeutic target in HS treatment.
What problem does this paper attempt to address?